
Inherited breast and ovarian cancer

Pr François Duhoux Medical Oncology and Clinical Genetics 9th February 2024


Accumulation of genetic alterations during carcinogenesis



Stratton MR, et al. Nature 2009 Membre du réseau Huni

Breast cancer Age-Standardized Rate (World) per 100 000, Incidence and Mortality, Females, in 2022 Breast Europe (Top 15) Incidence Mortality Incidence - Mortality France .be: 104.4 - 14.2 Cyprus Belaium -Lifetime risk : 12% Netherlands Luxembourg Norway Denmark United Kingdom Finland Ireland Portugal Italy Malta Greece Slove 20 40 60 80 100 120 ASR (World) per 100 000 International Agency for Research on Cancer Cancer TODAY | IARC - https://gco.iarc.who.int Data version: Globocan 2022 C All Rights Reserved 2024 (World Health Organization Membre du réseau Lid van het netwerk Huni 3

Breast cancer in Belgium according to age



Belgian Cancer Registry Membre du réseau Lid van het netwerk

Breast cancer: risk factors

- Sex
- 1 M / 100 F
- Age
- the risk increases with age
- but 15-20% before the age of 50
- Family history
- Personal history
- Environmental factors (geographic migration)
- Prolonged exposure to estrogens:
 - Early menarche
 - Late menopause
 - Late first pregnancy, few pregnancies
 - Lack of breast-feeding
- Other breast lesions (in situ carcinoma, atypical hyperplasia, radial scar, ...)
- Controversies: endocrine treatment for menopausal status, weight, alcohol, tobacco, ...

Lid van het netwerk

Breast cancer – genetic risk

- 15% of healthy women have at least one 1st degree relative with breast cancer \rightarrow risk x 2
- Breast cancer risk increases with the number of 1st degree relatives with breast cancer
 - 1: x 1.8
 - 2: x 2.9
 - 3: x 3.9
- BRCA1 and BRCA2 germline mutations are responsible for 20-25% of familial breast cancer cases, but
 5% of all breast cancers
- > 50% of the genetic predisposition to familial breast cancer remains unexplained





Ovarian cancer Age-Standardized Rate (World) per 100 000, Incidence and Mortality, Females, in 2022 Ovary Europe (Top 15) Incide Mortality Incidence - Mortality Latvia -.be: 6.9 – 3.7 Lithuania Poland Lifetime risk : 1.3% Russian Federation Ukraine Malta Croatia Cyprus Hungary Slovakia Bulgaria Ireland -Bosnia Herzegovina Romania Estonia ASR (World) per 100 000 Cancer TODAY | IARC - https://gco.iarcwho.int Data version: Globocan 2022 © All Rights Reserved 2024 International Agency 33/40 Belgium World Health Organization Membre du réseau Lid van het netwerk Huni 7


Ovarian cancer: risk factors

- Age
- Obesity
- Reproductive history
- Birth control
- Family history of breast, ovarian and colorectal cancer
- Personal history of breast cancer

Ovarian cancer genetics

23% of ovarian carcinomas have a hereditary predisposition

Germline BRCA1 and BRCA2 mutations account for 20-25% of high grade serous ovarian cancer



Toss A et al, Biomed Res Int 2015

Breast and ovarian cancer: multidisciplinary team



- surgeon / gynaecologist
- medical oncologist
- · radiation oncologist
- radiologist
- pathologist
- geneticist
- plastic surgeon

Membre du réseau Lid van het netwerk


6

Definitions

- Penetrance = the likelihood a given gene will result in disease
- High penetrance genes :
 - rare mutations
 - very high risk of disease
 - independently of other risk factors
- Low penetrance genes
 - frequent genetic variants
 - · interact with exogenous factors to cause the diseases

Lid van het netwerk


Genetic variants by risk and frequency



Easton D | Membre du réseau Huni | 12



Risk of breast cancer with proteintruncating variants in 34 genes



Breast Cancer Association Consortium, NEJM 2021

Guidelines for hereditary breast and/or ovarian cancer syndrome diagnostic testing criteria







New version : June 2023

I. Woman with breast cancer + one of the following:

diagnosed ≤ 40yrs

- diagnosed < 50yrs and one relative with bilateral breast cancer, or breast
- cancer < 50yrs, or prostate cancer diagnosed < 60yrs
- a first or second degree relative with male breast cancer, ovarian cancer, pancreatic adenocarcinoma, or metastatic prostate cancer
- bilateral breast cancer if the first cancer was diagnosed < 50yrs
- triple negative breast cancer < 60yrs
- HER2 negative (hormone receptor-negative or hormone receptor-positive) breast cancer eligible for PARP-inhibitors: in high-risk (neo)adjuvant setting or metastatic setting
- ovarian cancer or pancreatic adenocarcinoma at any age
 ≥ 3 individuals with breast cancer and/or prostate cancer, one is a first degree relative of the other two (excluding male transmitters if father is not
- affected) and one diagnosed at an early age (< 60yrs) individual of ethnicity associated with a higher frequency of specific
- mutations (e.g., Ashkenazi Jewish): eligible for founder mutation testing
 other family situations with a priori chance of mutation >10% according to
- BRCAPRO or Evans criteria or Manchester score

 test more than one affected relative if criteria remain positive after excluding
- the negative case as a phenocopy
- Women with high grade epithelial ovarian cancer at any age (excluding mucinous ovarian cancer)
- III. Male with breast cancer
- IV. Family history only
 - first degree unaffected relative of any of the above on a case-by-case basis
 testing of unaffected family members should only be considered when no affected family member is available and then the unaffected family member with the highest probability of mutation should be tested

Lid van het netwerk **Huni** 14


https://www.college-genetics.be/

BRCA1 and BRCA2




- Global prevalence of BRCA1 or BRCA2 mutations is estimated at 1/139 (Genome Medicine volume 12, Article number: 2 (2020))
- · Responsible for the majority of « hereditary » breast cancer cases
- 30 50% of breast cancer patients carrying a mutation have no known or significant family history (Eur J Cancer, 43 (11) (2007 Jul), pp. 1713–1717)
- Specific BRCA1 and BRCA2 mutations are frequent in the Jewish Ashkenazi population (1/40 1/50)

Lid van het netwerk Huni




Roles of *BRCA1* and *BRCA2* in hereditary breast and ovarian cancer syndrome (HBOC)

- High penetrance but variable expression :
 - Cumulative risk of breast cancer : up to 70 % (at 80 y.o.)
 - Ovarian cancer : 40% (BRCA1) / 20% (BRCA2)



Lid van het netwerk

HBOC : the cumulative cancer risk varies with age \rightarrow higher in younger women





BRCA1 and BRCA2

High penetrance : high risk of disease if mutation is found

But risk also depends on :

- Sex
- 1 M / 100 F
- Age
- the risk increases with age
- but 15-20% before the age of 50
- Family history
- Personal history
- Environmental factors (geographic migration)
- Prolonged exposure to estrogens:
 - Early menarche
 - Late menopause
 - Late first pregnancy, few pregnancies
 - Lack of breast-feeding
- Other breast lesions (in situ carcinoma, atypical hyperplasia, radial scar, ...)
- Controversies: endocrine treatment for menopausal status, weight, alcohol, tobacco, ...

Lid van het netwerk

BRCA1 and BRCA2

- Thousands of different sequence variants have been identified :
 - 1) mutations that are known or likely to be deleterious and disease-associated
 - 2) variants of unknown function
 - = UV : unclassified variants
 - 3) genetic variants that are likely to be neutral and without clinical importance





BRCA1 and BRCA2: beware of VUSs



• VUS = variant of unknown significance


Variant Class	Score: 1	Score: 2	Score: 3	Score: 4	Score: 5	
Interpretation	Not Pathogenic or of No clinical Significance	Likely Not Pathogenic or of Little Clinical Significance	Uncertain	Likely Pathogenic	Pathogenic	MUTATIONS
Probability of being pathogenic	<0.001	0.001-0.049	0.05-0.949	0.95-0.99	>0.99	
-						

IARC classification for sequence variants identified by genetic testing

Jimenez-Sainz et al, Genes 2021 | Membre du réseau Lid van Net netwerk

BRCA1 and BRCA2

Tumor	Risk	Comment
Breast cancer	60 – 80 % at 80 y	Higher risk for triple negative breast cancer
Contralateral breast cancer	Around 40% after 20 y	Risk table ¹ can be used during counseling for a more accurate risk estimate
Male breast cancer	1%	
Ovarian cancer	Around 40% at 80 y	
Prostate cancer	Moderate increase	
Pancreatic cancer	Small but increased risk	Not in patient folder
Endometrial cancer	< 5%	Should not be reported in patient folder
Colorectal cancer	Slight increase (only < 50 y)	Should not be reported in patient folder
Tumor	Risk	Comment
Breast cancer	60 – 80 % at 80 y	
Contralateral breast	Around 25% atter 20 v	Risk table ¹ can be used during counseling for a mor accurate risk estimate
cancer		accurate hisk estimate
cancer Male breast cancer	7%	
Male breast cancer	7%	
Male breast cancer Ovarian cancer	7% Around 20% at 80 y 15% before 65 y	Not in patient folder



Future risks of developing cancer for a female carrier at a range of ages in the next 10-year interval, 20-year interval, and so on

Chen, S. et al. J Clin Oncol; 24:863-871 2006

Annual Ovarian, Fallopian Tube and Peritoneal Cancer

			BRCA1				BRCA2	
Age Group (years)	No. of Patients	No. of Cancers	Person- Years	Annual Risk (per 100,000 per year)	No. of Patients	No. of Cancers	Person- Years	Annual Risk (per 100,000 per year)
30-34	413	2	865.6	231.1	47	0	90.4	0
35-39	566	6	2,223.1	269.9	92	0	388.7	0
40-49	1,009	43	3,958.6	1,086.2	276	1	1,174.3	85.2
50-59	549	34	2,029.9	1,675.0	207	5	853.2	586.1
60-69	216	9	975.3	922.8	98	3	475.2	631.3
70-74	128	4	659.1	606.9	59	1	363.2	275.3
Total	2.881	98	10,711.6	914.9	779	10	3,344.9	299.0

Finch, A. et al. J Clin Oncol; 2014 Membro du rézeau Lid van het netwerk

Guidelines for the management of patients with *BRCA1* mutations



Male breast cancer: Routine screening not recommended

PGD/PND for BRCA1? PGT is offered in every center; PND is not offered by every genetic center

Belgian guidelines for Managing Hereditary Breast and Ovarian Cancer: 05/2023 Update

https://www.college-genetics.be/

Guidelines for the management of patients with *BRCA2* mutations

Tumor	Intervention	Recommendation
Breast cancer	Screening	Clinical examination every 6 months from 25* y AND • 25* – 35 y: Annual breast MRI • Consider baseline mamogram once at 30y to detect potential microcalcifications • 35 – 65 y: annual breast MRI and annual mammogram (+/- Us when indicted by radiologist) alternating every 6 months • 65 – 75 y: Annual mammography (if quality is sufficient) • 75y: Consider mammogram every 2 y *Or 5 y younger than youngest diagnosis in the family if diagnosis <30y
	Risk reducing surgery	Bilateral mastectomy (comments: no standard follow-up with imaging after risk reducing mastectomy, nipple preservations is considered safe)
Ovarian cancer	Screening (not in folder)	Not recommended (comment: tailored program could be offered if patient refused risk reducing BSO ≥ 50 y)
	Risk reducing surgery	Strongly consider BSO < 50 y
Prostate cancer	Screening	Annual PSA and digital prostate exam from age 40 y (or 10y earlier than youngest diagnosis, whichever comes first)
	Smoke cessation	Recommended
Pancreatic cancer (not in folder)	Screening (preferentially in clinical trial)	If ≥1 first degree relative or ≥ 2 relatives of any degree with pancreatic cancer: consider discussing pros and cons of screening according to CAPS guidelines (Goggins et al, Gut 2020)
Male breast cancer:	Consider annual clir	ical exam by physician from age 40 y


PGD/PND for BRCA2? PGT is offered in every center; PND is not offered by every genetic center

Belgian guidelines for Managing Hereditary Breast and Ovarian Cancer: 05/2023 Update https://www.college-genetics.be/

Other genes implicated in an increased risk of breast cancer




Molecular mechanisms of double-strand break DNA repair



Nat Rev Cancer.;12(1):68-78 Membre du réseau

Estimated absolute risk of breast cancer associated with proteintruncating variants





Breast Cancer Association Consortium, NEJM 2021 Membre du research Huni

PALB2

- Breast (women) : cumulative risk 30-60%
 - · importance of family history
 - · increased risk of contralateral breast cancer
 - anticipation
- Ovary : cumulative risk 5-15%
- Breast (men) : 1%
- Pancreas: weak but increased

screening	Consider adaminator tevely of information (23.9 year) (25* – 35 y: Annual breast MMI Consider baseline mammogram once at 30y to detect potential microcaldifications 35 – 65 y: annual breast MRI and annual mammogram (+/- US when indicated by radiologist) alternating every 6 months 65 – 75 y: Annual mammography (if quality is sufficient) > 75y; Consider mammogram every 2 y ⁴ Or 5 y younger than youngest diagnosis in the family if diagnosis < 30y
Risk reducing surgery	Bilateral mastectomy (comments: no standard follow-up with imaging after risk reducing mastectomy, nipple preservations is considered safe)
Screening (not in folder)	Not recommended (comment: tailored program could be offered if patient refused risk reducing BSO \geq 50 y)
Risk reducing surgery	Strongly consider BSO at age of menopause (or earlier depending on family history
Smoke cessation	Recommended
Screening (preferentially in clinical trial)	If ≥1 first degree relative with pancreatic cancer: consider discussing pros and cons of screening according to CAPS guidelines (Goggins et al. Gut 2020)
	Risk reducing surgery Screening (not in folder) Risk reducing surgery Smoke cessation Screening (preferentially in

PGT is offered in every center; PND is not offered by every genetic center

Clinical examination every 6 months from 25* v AND

Belgian guidelines for Managing Hereditary Breast and Ovarian Cancer: 05/2023 Update https://www.college-genetics.be/

Lid van het netwerk Huni 29

CHEK2

- Breast (women) : cumulative risk 20-45%
 - · importance of family history
 - risk of contralateral cancer : 25% after 20 years
- Breast (men) : 0,5-1%
- Prostate : moderate increase

Tumor	Intervention	Recommendation
Breast cancer	Screening	Clinical examination every 6 months from 25 y AND 35 – 65 y: At least yearly breast MRI with 1-incidence mammogram +/- US if indicated by radiologist (or start 5 y before youngest diagnosis in family if diagnosis <40y) 65 – 75 y: Annual mammography (+/- ultrasound)
		 >759: Consider mammogram every 2 y (if patient is in good health)
	Risk reducing surgery	If strong family history or if diagnosed with breast cancer: consider risk reducing bilateral mastectomy
Prostate cancer	Screening	Annual PSA and digital prostate exam from age 50 y (or 10 y earlier than youngest diagnosis)

Female non-carriers with a 1st degree relative with breast cancer

Table 9: Recommendations for non-carrier with a first degree relatives (sister, daughter/mother) with breast cancer in CHEK2 families

	Tumor	Intervention	Recommendation
idelines for Managing Hereditary I Ovarian Cancer: 05/2023 Update	Breast cancer	Screening	40 – 50 y: Annual mammogram 50 – 75 y: Mammogram every 2 years
e-genetics.be/			Lid van het netwerk Huni

PGD/PND for PALB2?

Lid van het netwerk Huni 31

ATM

- Breast (women) : cumulative risk 30%
 - importance of family history
 - contralateral breast cancer?
- Breast (men) : 0,5-1%
- Prostate : moderate
- Pancreas : small

Tumor	Intervention	Recommendation
		Clinical examination every 6 months from 25 y AND
Breast cancer	Screening	35 – 65y: At least yearly breast MRI with 1-incidence mammogram +/- US if indicated by radiologist (or start 5 y before youngest diagnosi in family if diagnosis <40y) 65 – 75y: Annual mammogram (+/- ultrasound) >75y: Consider mammogram every 2 y (if patient is in good health)
	Risk reducing surgery	Bilateral mastectomy can be considered based on patient preference
Prostate cancer	Screening	Annual PSA and digital prostate exam from age 50 y (or 10y earlier than youngest diagnosis)
Pancreatic cancer	Smoke cessation	Recommended
(not in folder)	Screening (preferentially in clinical trial)	If ≥1 first degree relative with pancreatic cancer: consider discussing pros and cons of screening according to CAPS guidelines (Goggins et al, Gut 2020)

Female <u>non-carriers</u> with a 1st degree relative with breast cancer

Table 12: Recommendations for <u>non-carrier</u> with a first degree relatives (sister, daughter/mother) with breast cancer in ATM families Tumor Intervention Recommendation

 Tumor
 Intervention
 Recommendation

 Breast cancer
 Screening
 40 - 50 y: Annual mammogram

 50 - 75 y: Mammogram every 2 years

Belgian guidelines for Managing Hereditary Breast and Ovarian Cancer: 05/2023 Update https://www.college-genetics.be/

ΑΤΜ

- Risk of radiosensitivity in heterozygotes?
 - Not demonstrated : mammogram recommended by NCCN v1.2024, but caution advised by Belgian guidelines
- No evidence of deleterious effect of radiotherapy, but debated
- Beware of the risk of biallelic mutation in offspring:
- test the partner if child wish (risk 1/100)






Ataxia telangiectasia

- Congenital dysmorphic syndrome : small size, microcephaly, abnormal thumbs or forearms, face, neurological or retinian signs
- Predisposition to cancer (leukemia, lymphoma, carcinoma...)
 - +/- medullary insufficiency
 - +/- immune abnormalities

Int J Radiation Oncol Biol Phys, Vol. 105, No. 4, pp. 698e712, 2019



RAD51C and RAD51D

- Breast (women) : cumulative risk 20-45%
 - importance of family history
 - remaining risk in non-carriers
- Ovary: 5-10%

Tumor	Intervention	Recommendation	
		Clinical examination every 6 months from 25 y AND	
	Screening	 35 – 65 y: At least yearly breast MRI with 1-incidence mammogram +/- US if indicated by radiologist (or start 5 y bef youngest diagnosis in family if diagnosis <40y) 65 – 75 y: Annual mammography (+/- US when indicted by 	
Breast cancer		 65 – 75 y: Annual mammography (+/- US when indicted by radiologist) 	
		 >75y: Consider mammogram every 2 y (if patient is in good health) 	
	Risk reducing surgery	If strong family history or if diagnosed: consider risk reducing bilateral mastectomy	
Ovarian cancer	Screening (not in folder)	Not recommended (comment: tailored program could be offered if patient refused risk reducing BSO \geq 50 y)	
	Risk reducing surgery	Consider BSO < 50 y	

Comment: when a coincidental RAD51C/RAD51D mutation is found in absence of a family history of breast cancer (and an informative pedigree) it is reasonable to downgrade screening to annual mammogram starting at 40y, as breast cancer risk is estimated to be 20% for RAD51C/RAD51D women without family history

Female <u>non-carriers</u> with a 1st degree relative with breast cancer

Table 15: Recommendations for <u>non-carrier</u> with a first degree relatives (sister, daughter/mother) with breast cancer in RAD51/D families

Belgian guidelines for Managing Hereditary	Tumor
Breast and Ovarian Cancer: 05/2023 Update	
https://www.college-genetics.be/	Breast cancer

	Intervention	Recommendation	
er	Screening	40 – 50 y: Annual mammogram 50 – 75 y: Mammogram every 2 years	

Lid van het netwerk **Huni** 33

BARD1

- Breast (women) : cumulative risk 20-45%
 - importance of family history
 - · remaining risk in non-carriers
 - higher risk for TNBC

Tumor	Intervention	Recommendation
Breast cancer	Screening	Clinical examination every 6 months from 25 y AND • 35 – 65 y: At least yearly breast MRI with 1-incidence mammogram +/ US if indicated by radiologist (or start 5 y before youngest diagnosis in family if diagnosis -40y) • 65 – 75 y: Annual mammography (+/- ultrasound when indicted by radiologist) • 75 y: Consider mammogram every 2 y (if patient is in good health)
	Risk reducing surgery	If strong family history or if diagnosed: consider risk reducing bilateral mastectomy

Comment: when a coincidental BARD1 mutation is found in absence of a family history of breast cancer (and an informative pedigree) it is reasonable to downgrade screening to annual mammogram starting at 40y, as breast cancer risk is estimated to be lower for BARD1 women without family history

Female non-carriers with a 1st degree relative with breast cancer

Table 18: Recommendations for <u>non-carrier</u> with a first degree relatives (sister, daughter/mother) with breast cancer in BARD1 families

Tumor	Intervention	Recommendation
Breast cancer	Screening	40 – 50 y: Annual mammogram
		50 – 75 y: Mammogram every 2 years

Belgian guidelines for Managing Hereditary Breast and Ovarian Cancer: 05/2023 Update https://www.college-genetics.be/

BRIP1

- No increased risk of breast cancer
- Ovary: 5-10%

 Tumor
 Intervention
 Recommendation

 Ovarian cancer
 Screening (not in folder)
 Not recommended (comment: tailored program could be offered if patient refused risk reducing BSO ≥ 50 y)

 Risk reducing surgery
 Consider BSO < 50 y</td>

Belgian guidelines for Managing Hereditary Breast and Ovarian Cancer: 05/2023 Update https://www.college-genetics.be/

Lid van het netwerk Huni 35

Rare syndromes

- PTEN Cowden syndrome
 - Macrocephaly & autism
 - Hamartoma + trichilemmoma
 - Increased risk of breast cancer (60% at 70 y.o.) + thyroid carcinoma + endometrium + colon
- STK11 Peutz-Jeghers syndrome
 - Hamartoma
 - Abnormal pigmentation of skin and mucosa
 - Increased risk of breast cancer (40-60% at 70 y.o.) + cervix and endometrium + digestive tract + pancreas + lung + sex cord tumors










Rare syndromes

- CDH1
 - Lobular breast cancer (60% at 80 y.o., bilateral)
 - Diffuse gastric cancer
 - Cleft lip and palate



• TP53 – Li-Fraumeni syndrome

- De novo mutations (7-20%), mosaicism ightarrow family history not always present
- Breast cancer (HER2+) 6% of women with breast cancer < 30 y.o; risk >60%
- Sarcoma
- Adrenocortical carcinoma
- Leukemia
- Brain tumor
- Other cancers (lung, colon, pancreas, genito-urinary, skin, prostate, ...)



AVOID RADIATION

Membre du réseau Lid van het netwerk **Huni**

Li-Fraumeni syndrome: heterozygous *TP53* mutation




Table	1 . 2009	Chompret	Criteria f	for	Germline	TP53	Mutation	Screening
-------	-----------------	----------	------------	-----	----------	------	----------	-----------



	Criterion
Ι.	Proband with tumor belonging to LFS tumor spectrum (eg, soft tissue sarcoma, osteosarcoma, brain tumor, premenopausal breast cancer, adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before age 46 years AND at least one first- or second-degree relative with LFS tumor (except breast cancer if proband has breast cancer) before age 56 years or with multiple tumors; OR
II.	Proband with multiple tumors (except multiple breast tumors), two of which belong to LFS tumor spectrum and first of which occurred before age 46 years; OR
111.	Patient with adrenocortical carcinoma or choroid plexus tumor, irrespective of family history

Abbreviation: LFS, Li Fraumeni syndrome.


BUT : nowadays, included in panel testing!!!


J Clin Oncol. 2009 Sep 10;27(26):e108-9

Other genetic predisposition factors to breast and/or ovarian cancer

- Lynch syndrome
- ...

 \rightarrow Pr De Leener





Multifactorial cancer risk prediction If no genetic alteration is found --> importance of family history (and other risk factors!)



• Software for risk assessment



https://www.canrisk.org/


Polygenic risk scores and family history

Has a SNP array	/ Polygenic	: Risk Score (P	RS), ever been run?				Have you any Ashkenati Jewish ancestors? Ashkenati Jewish 🔮 Other / Unknown	0		I HINT! The Leaf betton at the top of the tool can be used to load a pe file (e.g. BOADICEA file format exported from phenotips).
Upload a VCF (V	ariant Call For	rmat) file 🥝 Ente	r PRS values						0008	Advanced Options - Ed
Breast Cancer BCAC 313 Breast Cancer PRS: 54% of people in the load. 46% of people in the polygenic load.	population ha		Ovarian Cancer Select a reference	alpha alpt	z-score Z-SI	0			Mark 2	Indukur) pools I take Teach I take
Algorithm of the second	olygenic Load						Colore Anthony			<u>CanR</u> isk


Antonis C.Antoniou, ESMO Breast 2023 Meretered under Huni 44

313 SNP Polygenic Risk Score – Breast Cancer

- Breast Cancer Association Consortium (BCAC)
- 94,094 breast cancer cases and 75,017 control women
- SNPs act multiplicatively on risk
- Validated in prospective cohorts
- Explains 20% of Familial Risk




Mavaddat et al, AJHG 2019 Membre du réseau Lid van het netwerk Huni 45



Lid van het netwerk Huni 46

BRCAtool



http://brcatool.stanford.edu/

BRCA1 and **BRCA2**: how to interpret the results?




- · Many mutations, different from one family to another
- A clearly deleterious mutation cannot be identified in all cases
- \rightarrow 2-step process :
 - Index case (usually a family member treated for cancer at a young age)
 - then analyze the relatives, if appropriate (usually asymptomatic)
- If **no mutation** could be identified after the analysis of the index case, the test should be considered as **non informative**, because the presence of a deleterious mutation cannot be excluded, and no presymptomatic test can be offered to the relatives
- If a **mutation** is identified, a **predisposition test** can be offered to the relatives : if it is negative, it can be concluded that the relative has not inherited the familial predisposition factor
- Minors : no indication to test



PARP Inhibitors







Lid van het netwerk **Huni**

BRCA1 Dysfunction and PARP Inhibition

CONCEPT OF SYNTHETIC LETHALITY Cell death by dual targeting of pathways that, in isolation, are not lethal




Adapted from Comen EA, et al. Oncology. 2010;24:55-62.



A Mechanisms of PARPi linked to BER/HRR nexus for tumors with BRCA mutations or BRCAness phenotype


B Mechanisms of PARPi linked to other target pathways






Litton J et al, NEJM 2018; Robson M et al, NEJM 2017 | Membre du réseau Huni 53

Olympia : trial schema




Tutt A et al, ASCO 2021 | Membre du réseau Huni 54

Olympia : pre-specified IA 2



Geyer CE et al, Ann Oncol 2022 Membre du réseau Lid van het netwerk Huni 55

Olympia : pre-specified IA 2



Geyer CE et al, Ann Oncol 2022 Membre du réseau Lid van het netwerk Huni 56

Olympia : subgroup analyses

Subgroup	Olaparib	Placebo	3-Yr Invasive Disease–free Survival		Stratified Hazard Ratio for Invasive Disease or Death (95% CI)		
			Olaparib	Placebo			
	no. of patie event/t	nts with an otal no.	%	5			
All patients	106/921	178/915	85.9	77.1		0.58 (0.46-0.74)	
Timing of previous chemotherapy							
Neoadjuvant	70/460	117/460	82.5	68.0		0.56 (0.41-0.75)	
Adjuvant	36/461	61/455	89.3	85.4		0.60 (0.39-0.90)	
Previous platinum-based chemotherapy							
Yes	34/247	43/239	82.0	77.0		0.77 (0.49-1.21)	
No	72/674	135/676	87.3	77.1		0.52 (0.39-0.69)	
Hormone-receptor status							
HR+ and HER2-	19/168	25/157	83.5	77.2		0.70 (0.38-1.27)	
TNBC	87/751	153/758	86.1	76.9	_	0.56 (0.43-0.73)	
Germline BRCA mutation							
BRCA1	70/558	126/558	85.0	73.4		0.52 (0.39-0.70)	
BRCA2	22/230	38/209	88.6	78.0 -		0.52 (0.30-0.86)	
BRCA1 and BRCA2	0/1	0/3	NC	NC		NC	
Hormone-receptor status and timing of previous chemotherapy							
HR+ and HER2-, NACT	13/104	20/92	86.0	67.0		0.52 (0.25-1.04)	
HR+ and HER2-, ACT	6/64	5/65	76.4	89.3		→ 1.36 (0.41-4.71)	
TNBC, NACT	57/354	97/368	81.4	67.7		0.57 (0.41-0.79)	
TNBC, ACT	30/397	56/390	90.3	84.8		0.54 (0.34-0.83)	
Previous platinum-based chemotherapy and timing of previous chemotherapy							
Yes, NACT	26/169	39/169	81.8	70.1		- 0.66 (0.40-1.07)	
Yes, ACT	8/78	4/70	NC	NC		NC	
No, NACT	44/291	78/291	83.1	66.8		0.51 (0.35-0.73)	
No, ACT	28/383	57/385	90.4	84.2		0.51 (0.32-0.79)	
CPS+EG score in patients with previous NAC	r						
Score of 2, 3, or 4	55/398	96/387	84.3	68.9		0.51 (0.37-0.71)	
Score of 5 or 6	11/22	10/15	50.0	17.9		- 0.44 (0.19-1.06)	
Primary database							
Breast International Group	95/810	160/806	86.0	76.7		0.58 (0.45-0.75)	
NRG Oncology (United States)	11/111	18/109	85.0	80.6	-	0.57 (0.26-1.18)	
				0.25	0.50 0.75 1.00	1.25	
				•	Olaparib Better	Placebo Better	

Tutt et al, NEJM 2021 | Membre du réseau Huni | 57

Olympia : adverse events


Adverse event, no. of patients (%)	Olaparib (n = 911)	Placebo (n = 904)
Any adverse event	836 (91.8)	758 (83.8)
Serious adverse event	79 (8.7)	78 (8.6)
Adverse event of special interest ^b	31 (3.4)	51 (5.6)
MDS/AML	2 (0.2)	3 (0.3)
Pneumonitis ^c	9 (1.0)	12 (1.3)
New primary malignancy ^d	21 (2.3)	36 (4.0)
Grade \geq 3 adverse event	223 (24.5)	102 (11.3)
Grade 4 adverse event ^e	17 (1.9)	4 (0.4)
Adverse event leading to permanent discontinuation of treatment ${\ensuremath{^{\rm f}}}$	98 (10.8)	42 (4.6)
Adverse event leading to death ^g	1 (0.1)	2 (0.2)

Olympia : practical considerations

- Not to combine with adjuvant radiotherapy (not permitted in OlympiA no safety data)
- Safe to combine with adjuvant endocrine therapy
- Start no earlier than 2 weeks and no later than 12 weeks from trial enrolment
 - from surgery, end of adjuvant chemotherapy or end of adjuvant radiotherapy if administered, whichever is latest

Geyer CE et al, Ann Oncol 2022 | Membro du réseau Lid van het netwerk Huni | 59


Identifying High Risk EBC Patients for Adjuvant Olaparib



NeoTALA : trial schema




NEOTALA is a non-randomized, open-label, multi-center, single-arm, Phase 2 trial (NCT03499353)



EFS=event-free survival; HR=hormone receptor; ICR=independent central review; INV=investigator; OS=overall survival. "Study design was amended to include HR-positive, HER2-negative patients with BC and the patient numbers were reduced from 112 to 60 in order to address lower than expected enrollment. "Breadsularity issue must be memore they ofther functionary with the cate of surgery for EFS and after the first dose of drugs regretative address in the setting from the cate of surgery for EFS and after the first dose of drugs regretative address and training from the cate of surgery for EFS and after the first dose of drugs regretative address and training from the cate of surgery for EFS and after the first dose of drugs regretative address and training from the cate of surgery for EFS and after the first dose of drugs regretative address and training from the cate of surgery for EFS and after the first dose of drugs regretative address and training from the cate of surgery for EFS and after the first dose of drugs regretative address and training from the setting. The today was not reached.



NeoTALA : pCR rate



Litton JK et al, ASCO 2021 Membre du réseau Huni 62

Phase II study of maintenance olaparib in ovarian cancer: study 19

Patients

Platinum-sensitive high-grade serous ovarian cancer ≥2 previous platinum regimens Maintained PR or CR following last platinum regimen




Primary endpoint PFS by RECIST Secondary endpoints TTP by CA-125 (GCIG criteria) or RECIST, OS, safety

82 sites in 16 countries

Ledermann et al. J Clin Oncol 2011;29 (suppl; abstr 5003); N Engl J Med. 2012 Apr 12;366(15):1382-92

Study 19: progression-free survival



Ledermann et al. J Clin Oncol 2011;29 (suppl; abstr 5003); N Engl J Med. 2012 Apr 12;366(15):1382-92

Study 19: common adverse events*


		=136)	(n=128)		
		Percentage	of Patients		
Adverse event	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4	
Any event	61	35	70	20	
Nausea	66	2	35	0	
Fatigue	42	7	34	3	
Vomiting	29	2	13	1	
Diarrhea	21	2	20	2	
Headache	18	0	11	1	
Decreased appetite	18	0	13	0	
Abdominal pain	16	2	23	3	
Anemia	12	5	4	1	
Dyspepsia	16	0	9	0	

*Adverse events graded according to maximum CTCAE version 3.0 grade, experienced by >15% of patients in either treatment group.

Ledermann et al. J Clin Oncol 2011;29 (suppl; abstr 5003); N Engl J Med. 2012 Apr 12;366(15):1382-92

Study 19: PFS by BRCAm status





82% reduction in risk of disease progression or death with olaparib

Study 19: PFS by BRCAm status BRCAm (n=136) BRCAwt (n=118) Placebo Olaparib Placebo Events: total pts (%) 46:62 (74.2) 32:57 (56.1) 44:61 (72.1) 1.0 Median PFS, months 4.3 5.6 5.5 Proportion of patients progression-free 0.9 HR=0.18 HR=0.53 0.8 95% CI (0.11, 0.31); 95% CI (0.33, 0.84); P=0.007 P<0.00001 0.7 0.6 0.5 0.4 0.3 **Olaparib BRCAm** Placebo BRCAm 0.2 Olaparib BRCAwt 0.1 Placebo BRCAwt 0 12 15 3 6 q Time from randomization (months) Number at risk Placebo BRCAm 62 35 13 2 0 0 Olaparib BRCAwt 57 44 17 9 2 0 Placebo BRCAwt 61 35 10 4 1 0

BRCAwt, wild type (includes patients with no known BRCAm or a mutation of unknown significance)

Presented by: Jonathan Ledermann et al at ASCO 2013

Memila Zu réseau Lid van het netwerk

General conclusions

- Breast cancer is frequent ovarian cancer is rare
- Genetic predisposition is only partially explained by BRCA1/2 mutations
 - +/- 10% of breast cancers are due to a genetic predisposition
 - < 5% are due to BRCA1 or BRCA2 germline mutations
 - Multiple different mutations exist
 - · Only patients with a high probability of mutation should be tested
 - · Other, rare genetic anomalies exist
- PARP inhibitors are now established treatment options for BRCAm breast and ovarian cancer patients
- · Future breast and ovarian cancer treatments will take into account constitutional and somatic GENETIC alterations







